Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics by ruth on December 15, 2005

Amgen and Abgenix have been collaborating on developing two major cancer drug candidates, one of which, panitumumab, has been shown effective against colorectal cancer therapy in its Phase 3 clinical trials. If approved by the FDA (they will file for FDA approval next week), the drug, which is an epidermal growth factor receptor inhibitor, is expected to have billion dollar potentials. Amgen's press release says that Amgen gains full ownership over panitumumab, as well as another cancer drug candidate, denosumab:

The acquisition of Abgenix provides Amgen with full ownership of one of its most important advanced pipeline products, panitumumab. Working closely with Abgenix under a co-development agreement that Amgen assumed as a result of its acquisition of Immunex Corporation in 2002, Amgen has led the development and commercialization strategy for panitumumab. The acquisition provides additional value to Amgen by eliminating a tiered royalty that Amgen would have paid to Abgenix on future sales of denosumab (formerly AMG 162), which was created using Abgenix's XenoMouse(R) antibody technology.

Webcast of the conference call regarding the merger is available here.

Source: Amgen

Related Entries:

Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate F... - 14 February 2006
Amgen's Denosumab Increases Bone Mineral Density in Phase 2 ... - 27 February 2006
Amgen Seeks Banning of Roche's Anemia Drug, Cera - 12 April 2006
Amgen Buys Ilypsa for $420 Million - 06 June 2007

« Gene Therapies Against Pa... | Main | Transgenic Tomatoes Resis... »

Permalink: Amgen Acquires Abgenix for $2.2 B

Tags: amgen cancer biotech abgenix acquires amgen+acquires acquires+abgenix please+enter

Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/12384

Addthis

Ask

Blinklist

del.icio.us

Digg

Fark

Facebook

Google

Lycos

Ma.gnolia

Mr Wong

Netscape

Netvousz

Newsvine

StumbleUpon

Slashdot

Tailrank

Technorati

Wink

Yahoo

Vote for Amgen Acquires Abgenix for $2.2 B:

Currently 6.00/10
1
2
3
4
5
6
7
8
9
10

Rating: 6.00 out of 2 vote(s) cast.

Response from: Guillaume Champeau (12/15/05 11:58am)

Hi Ruth,

Thank you for the quality of your blog, I very much like it.

Would it be please possible to know your email address? I am working on a project I'd very much like you to be involved in.

You may post the address here or otherwhise send it to me at champeau |at| agoravox.com

Read you soon,
G.C.

Add your response to Amgen Acquires Abgenix for $2.2 B:

Name: *

Email: (will never be shown)*

URL:

(* marked fields are required)

Notify me if more comments appear?

Subscribe to The Biotech Weblog newsletter? (Newsletters are sent out weekly).

Remember me

Security Code: *
(Please help us to sort out spam.)

Please enter your comment here: (Sorry, no HTML is allowed - URLs will be made clickable automatically if you add http:// to your URL.)

We welcome your comments, however all comments are moderated. Offensive or off-topic comments will be deleted and not displayed.

Share It

Use the search to look for other interesting posts

Contributors (Last 90 days)

Shawn Hessinger (1)
Gloria Gamat (5)
Ruth Schaffer (14)
Creative Weblogging (3)

This site has 1333 entries and is powered by Creative Weblogging since July 2005.

Our Editors recommend

Disclaimer

Some of the contents of this site are protected Creative Weblogging Inc. 2004-2010.

Check out our Sponsored Blogs!

Business Computer Blog (UK)

Are you interested in writing a blog in our network?

See which positions are currently open.

Testimonials

'Very nice blog layout with great content. Are you interested in Star Trek props that are quickly becoming reality? Then this is the blog for you. Human medical scanners, nano technology and more great technological advancements.' -VirtualLoop Blog of the Week

'I subscribe to your blog and have been enjoying your posts and perspective.'